Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

Related Articles by Review for PubMed (Select 22231760)

1.

Prostate cancer in 2011: Hitting old targets better and identifying new targets.

Chen Y, Scher HI.

Nat Rev Clin Oncol. 2012 Jan 10;9(2):70-2. doi: 10.1038/nrclinonc.2011.213. Review.

PMID:
22231760
2.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
3.

Castration-resistant prostate cancer: targeted therapies.

Leo S, Accettura C, Lorusso V.

Chemotherapy. 2011;57(2):115-27. doi: 10.1159/000323581. Epub 2011 Mar 24. Review.

PMID:
21430379
4.
5.

PSA relapse prostate cancer: the importance of tailored therapy.

Aranha O, Vaishampayan U.

Urol Oncol. 2004 Jan-Feb;22(1):62-9. Review.

PMID:
14969807
6.

Unanswered questions in screening for prostate cancer.

Neal DE, Leung HY, Powell PH, Hamdy FC, Donovan JL.

Eur J Cancer. 2000 Jun;36(10):1316-21. Review.

PMID:
10882874
7.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
8.

The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century.

Vaishampayan U, Hussain M.

Crit Rev Oncol Hematol. 2002 May;42(2):179-88. Review.

PMID:
12007976
10.

Prospective new developments in laboratory research and clinical trials in prostatic cancer.

Horoszewicz JS, Murphy GP.

Cancer. 1990 Sep 1;66(5 Suppl):1083-5. Review.

PMID:
2203519
11.

Controversies in the early detection of prostate cancer.

Montie JE.

In Vivo. 1994 May-Jun;8(3):407-11. Review.

PMID:
7528555
12.

Prostate cancer screening.

Tenke P, Horti J, Balint P, Kovacs B.

Recent Results Cancer Res. 2007;175:65-81. Review.

PMID:
17432554
13.

The socioeconomic implications of prostate-specific antigen screening.

Benoit RM, Naslund MJ.

Urol Clin North Am. 1997 May;24(2):451-8. Review.

PMID:
9126243
14.

Prostate cancer screening.

Cook ED, Nelson AC.

Curr Oncol Rep. 2011 Feb;13(1):57-62. doi: 10.1007/s11912-010-0136-x. Review.

PMID:
20981510
15.

Can screening for early-stage prostate cancer be rationalized?

Jacobson JO.

Hematol Oncol Clin North Am. 1996 Jun;10(3):549-64. Review.

PMID:
8773496
16.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
18.

Future studies in localized prostate cancer. What should we think? What can we do?

Lange PH.

J Urol. 1994 Nov;152(5 Pt 2):1932-8. Review.

PMID:
7933250
19.

Updates on therapeutic targets and agents in castration-resistant prostate cancer.

Bishr M, Lattouf JB, Gannon PO, Saad F.

Minerva Urol Nefrol. 2011 Jun;63(2):131-43. Review.

PMID:
21623331
20.

Targeted therapy for advanced prostate cancer: Looking through new lenses.

Vogiatzi P, Cassone M, Claudio L, Claudio PP.

Drug News Perspect. 2009 Dec;22(10):593-601. doi: 10.1358/dnp.2009.10.1428872. Review.

PMID:
20140279
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk